What are the recommended dosing regimens for β‑blockers, digoxin, anticoagulation, and antiarrhythmic agents in a pregnant patient with atrial fibrillation?

Dosing for Atrial Fibrillation in Pregnancy

For pregnant patients with atrial fibrillation, the ESC guidelines explicitly defer to standard AF management guidelines for specific drug dosing, but the framework prioritizes rate control with β-blockers (metoprolol or propranolol, NOT atenolol) or digoxin, with anticoagulation using warfarin (substituted with heparin in first and last trimester), and rhythm control reserved for symptomatic cases using flecainide or propafenone in conjunction with AV nodal blockers 1, 2.

β-Blocker Dosing

• Preferred agents: Metoprolol or propranolol (oral formulations)
• Avoid atenolol completely - it is contraindicated for any arrhythmia in pregnancy due to fetal growth restriction risk 1
• Use with caution in first trimester - all β-blockers carry some risk of fetal growth restriction, though metoprolol and propranolol are safer than atenolol 1
• Standard non-pregnant dosing applies, but guidelines direct clinicians to published AF management protocols for exact regimens 1

Digoxin Dosing

• Loading dose: 0.5 mg every 8 hours for 24 hours (three doses total)
• Maintenance: 0.5 mg every 12 hours 3
• Monitoring: Serum digoxin concentrations should be routinely monitored and adjusted, particularly in third trimester when drug disposition increases significantly (volume of distribution ~682-731 L, clearance ~16-19 L/h) 3
• Target SDC: 0.8-1.5 ng/mL for rate control, though pregnancy-specific targets are not well-established 4
• Digoxin can be used for rate control, particularly when added to β-blockers if monotherapy fails 2

Anticoagulation Dosing Strategy

Critical timing-based algorithm 1, 2:

First Trimester (Weeks 1-12)

• Switch from warfarin to heparin to avoid warfarin embryopathy
• Use unfractionated heparin (UFH) or low molecular weight heparin (LMWH) at weight-adjusted therapeutic doses
• LMWH preferred for ease of administration

Second Trimester (Weeks 13-36)

• Warfarin can be used - cross placental barrier but organogenesis complete
• Dose to target INR per standard AF guidelines (typically 2-3)

Last Trimester and Near Delivery (Week 36+)

• Switch back to UFH or LMWH to minimize bleeding risk at delivery
• Warfarin crosses placenta and increases fetal intracranial hemorrhage risk during delivery

Peri-Cardioversion Anticoagulation

• AF duration ≥48 hours or unknown: Anticoagulate for minimum 3 weeks before elective cardioversion, continue minimum 4 weeks after 1, 2
• AF duration <48 hours: IV heparin or therapeutic LMWH peri-cardioversion may be considered without prolonged pre-treatment if no thromboembolic risk factors 1
• Transoesophageal echo can exclude thrombus to allow cardioversion with <3 weeks anticoagulation 2

Direct oral anticoagulants (DOACs) are contraindicated - insufficient safety data in pregnancy 5

Antiarrhythmic Drug Dosing for Rhythm Control

Acute Pharmacological Cardioversion (if hemodynamically stable)

• IV ibutilide or IV flecainide - limited pregnancy experience but may be considered 1
• IV propafenone - even less experience, use only if other options fail 1
• Amiodarone NOT recommended unless all other options fail due to fetotoxic effects (thyroid dysfunction, growth restriction) 1

Long-term Rhythm Control (if symptomatic despite rate control)

• Flecainide or propafenone - must be used in conjunction with AV nodal blocking agent (β-blocker or digoxin) to prevent 1:1 AV conduction 1, 2
• Sotalol - can be considered as alternative 1
• Standard non-pregnant dosing regimens apply per AF guidelines 1
• Contraindication: Do not use flecainide/propafenone in moderate-severe structural heart disease 2

Electrical Cardioversion

• Immediate synchronized cardioversion for hemodynamic instability at any gestational age 1, 2
• Safe for mother and fetus, does not require anesthesia modification 1

Critical Pitfalls to Avoid

1. Never use atenolol - specifically contraindicated in pregnancy guidelines 1
2. Never use DOACs - no safety data in pregnancy 5
3. Never use flecainide/propafenone without rate control agent - risk of 1:1 AV conduction and paradoxical tachycardia 1, 2
4. Never delay cardioversion if hemodynamically unstable - maternal instability threatens fetal perfusion 1, 2
5. Never forget to switch anticoagulation regimen at first trimester and before delivery 1
6. Avoid amiodarone except as last resort - significant fetal thyroid and growth effects 1

Clinical Decision Algorithm

Step 1: Assess hemodynamic stability

• Unstable → immediate electrical cardioversion
• Stable → proceed to Step 2

Step 2: Determine AF duration and anticoagulation needs

• Duration ≥48h or unknown → anticoagulate 3 weeks before elective cardioversion
• Duration <48h → consider immediate cardioversion with peri-procedural anticoagulation

Step 3: Choose rate vs rhythm control strategy

• Rate control first-line: β-blocker (metoprolol/propranolol) ± digoxin
• Rhythm control if symptomatic: Flecainide or propafenone PLUS β-blocker/digoxin

Step 4: Anticoagulation based on gestational age

• Weeks 1-12: LMWH/UFH
• Weeks 13-36: Warfarin acceptable
• Week 36+: Switch to LMWH/UFH